Literature DB >> 27113952

Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.

Upinder Kaur, Sankha Shubhra Chakrabarti, Indrajeet Singh Gambhir1.   

Abstract

Zoledronate is a Nitrogen containing bisphosphonate (NBP) used in many conditions like osteoporosis, Paget's disease and hypercalcemia of malignancy. Unlike oral bisphosphonates, Zoledronate is not seen to be associated with gastroesophageal side effects but the drug is not free of certain rare but life threatening adverse effects like hypocalcemia and renal deterioration. Majority of cases of hypocalcemia with Zoledronate are seen in patients with underlying malignancy and are asymptomatic. Here we present a case of severe symptomatic hypocalcemia along with hypophosphatemia following zoledronate administration in an elderly male with a history of osteoporotic fracture.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27113952     DOI: 10.2174/1574886311666160426141647

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  5 in total

1.  Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis.

Authors:  Antonella Tufano; Domenico Rendina; Paolo Conca; Beniamino Matani; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2019-02-15       Impact factor: 3.397

2.  Zoledronic acid combined with percutaneous kyphoplasty in the treatment of osteoporotic compression fracture in a single T12 or L1 vertebral body in postmenopausal women.

Authors:  J Zhang; T Zhang; X Xu; Q Cai; D Zhao
Journal:  Osteoporos Int       Date:  2019-04-11       Impact factor: 4.507

Review 3.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

4.  Zoledronic Acid-Associated Fanconi Syndrome in Patients With Cancer.

Authors:  Ignacio Portales-Castillo; David B Mount; Sagar U Nigwekar; Elaine W Yu; Helmut G Rennke; Shruti Gupta
Journal:  Am J Kidney Dis       Date:  2022-02-24       Impact factor: 11.072

5.  Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis.

Authors:  Louise Wulff Bagger; Per Kim Dyhr Hansen; Peter Schwarz; Barbara Rubek Nielsen
Journal:  BMJ Case Rep       Date:  2020-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.